AnaConDa-therapy in COVID-19 Patients
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Sponsor
- Enrollment
- 42
- Locations
- 1
- Primary Endpoint
- P/F ratio
Study Overview
Brief Summary
COVID 19-pneumonia may evolve into respiratory insufficiency for which invasive mechanical ventilation is required. Recently, inhaled anesthetics have become available for sedation of critically ill patients. Based upon recent research, these anesthetics may provide advantages in improvement of P/F ratio in ARDS patients. However, up to now, its effects on COVID-19 pneumonia patients is unknown; therefore, this study was designed as a plan to investigate whether the use of inhaled sevoflurane leads to improvement of oxygenation compared to intravenous sedatives in mechanically ventilated COVID-19 patients
Detailed Description
COVID-19 is an infectious disease caused by the virus SARS-CoV-2, which can lead to severe pneumonia with acute respiratory distress syndrome (ARDS)-like presentation. In this condition, the exchange of oxygen and carbon dioxide in the lungs is compromised because of an inflammatory response with capillary leak. This leads to deterioration of oxygenation with hypoxemia and a decrease in P/F (arterial oxygen tension/fraction of inspired oxygen) ratio, resulting in need for invasive mechanical ventilation. To accomplish this, the patient needs to be sedated. Classic, intravenous sedatives usually come with long half-lifes, which lead to prolonged need for mechanical ventilation, because of residual sedation. Next to short half-life, the inhalation anesthetic sevoflurane is supposed to have anti-inflammatory effects, which could improve oxygenation.
This study is designed to investigate the hypothesis that sedation by use of sevoflurane leads to better oxygenation in COVID-19 patients, compared to intravenous sedatives.
Secondarily, the effects of sevoflurane compared to intravenous sedatives on duration of admission and mechanical ventilation, on respiratory parameters and hemodynamics, inflammatory parameters, use of opioids, manner of waking up and prevalence of delirium, will be investigated.
Study design: The study concerns a single center cohort study in the ICU of the Jeroen Bosch Hospital in The Netherlands. Inhaled anesthesia by sevoflurane is compared to intravenous sedation. Both are considered to be standard of care.
Study population: Patients with respiratory insufficiency due to COVID-19 pneumonia, with need for invasive mechanical ventilation on the ICU in the Jeroen Bosch Hospital.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Age >18 years
- •More than 24 hours of invasive mechanical ventilation needed
- •Positive test (e.g. Polymerase Chain Reaction (PCR)) for SARS-CoV-2
Exclusion Criteria
- •pulmonary history
- •known allergy or hypersensitivity for halogenated anesthetics
- •known or suspected predisposition for malignant hyperthermia
- •suspected or proven intracranial hypertension
- •severe liver dysfunction and/or icterus (serum bilirubin >42,8-51,3 μg per liter)
- •neutropenia (<0.5X10^9 neutrophils per liter)
- •chemotherapy in the month prior to ICU admission
- •patients that are transported to other hospitals during admission
Arms & Interventions
Sevoflurane
patients admitted because of respiratory insufficiency due to COVID-19 with need for invasive mechanical ventilation that are sedated by using sevoflurane
Intervention: Sevoflurane (Drug)
Outcomes
Primary Outcomes
P/F ratio
Time Frame: day 2 after intubation
arterial oxygen tension divided by fraction of inspired oxygen
Secondary Outcomes
- duration of ICU admission(through ICU admission)
- 28VFD(28 days after intubation)
- 28DFD(28 days after intubation)
- need for vasopressors(duration of ICU stay)
- 28DM(28 days after intubation)
- P/F ratio day 5(day 5 after intubation)
Investigators
K.S. Simons
MD, PhD
Jeroen Bosch Ziekenhuis